VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2017 | Overcoming the limits: bringing CAR T-cell therapy to the masses

The stimulating area of CAR T-cell therapy is currently limited due to a range of factors, which must be overcome in order to allow the widespread dissemination of this practice-changing treatment. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Abramson provides a comprehensive overview of the hurdles to accessing CAR T-cell therapy, including the interesting areas of logistics, HCP education, and in-patient vs. out-patient usage. Jeremy Abramson, MD, of Massachusetts General Hospital, Boston, MA, follows up this thorough summary by stating how these challenges can be remedied.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter